{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:59:20Z","timestamp":1782233960588,"version":"3.54.5"},"reference-count":14,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Oncocytic adrenal carcinoma (OAC) is a rare histologic subtype of adrenal cortical carcinoma (ACC) characterized by &amp;gt;90% oncocytic cells. Unlike ACC, OACs have a reduced incidence of adrenal hormone production, larger size, and longer time to recurrence (17.5 months vs 8 months). Genetic mutations in CTNNB1 are associated with decreased survival in ACC but their role in OAC is unknown. Here, we present a case of OAC highlighting the importance of comprehensive genomic profiling in predicting time to recurrence. A 72-year-old woman presented with rapidly progressive muscle weakness, new-onset type 2 diabetes mellitus, resistant hypertension associated with hypokalemia, and profound cognitive decline. Hormonal evaluation was consistent with ACTH-independent Cushing syndrome. A computed tomography scan of the abdomen showed a 7.1-cm heterogenous left adrenal mass. Pathology confirmed OAC after an en bloc left adrenalectomy. Next-generation sequencing revealed somatic mutations in CTNNB1, CDKN2A, and CDKN2B. Disease progression at 5 months after left adrenalectomy was comparable to other histopathological types of ACC, emphasizing the impact of genomic alterations in OAC.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf227","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:13:36Z","timestamp":1759824816000},"source":"Crossref","is-referenced-by-count":1,"title":["Genomic Sequencing in Oncocytic Adrenal Carcinoma May Provide Insights into Disease Progression and Treatment Options"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8313-8456","authenticated-orcid":false,"given":"Hye Jeong","family":"Han","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology & Metabolism, University of Rochester , Rochester, NY 14642 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Surgical Oncology, University of Rochester , Rochester, NY 14642 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Numbereye","family":"Numbere","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester , Rochester, NY 14642 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7130-7366","authenticated-orcid":false,"given":"Adrienne","family":"Victor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology & Oncology, University of Rochester , Rochester, NY 14642 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6254-237X","authenticated-orcid":false,"given":"Inga","family":"Harbuz-Miller","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology & Metabolism, University of Rochester , Rochester, NY 14642 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"21","key":"2025100913171490600_luaf227-B1","doi-asserted-by":"crossref","first-page":"6925","DOI":"10.3390\/jcm12216925","article-title":"Prognosis of Adrenal Oncocytic Neoplasms (AONs): literature review of 287 cases and presentation of the oldest patient","volume":"12","author":"Coppola","year":"2023","journal-title":"J Clin Med"},{"issue":"2","key":"2025100913171490600_luaf227-B2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000345141","article-title":"Adrenal oncocytic neoplasm: a systematic review","volume":"91","author":"Mearini","year":"2013","journal-title":"Urol Int"},{"issue":"4","key":"2025100913171490600_luaf227-B3","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.surg.2019.05.049","article-title":"Oncocytic subtypes of adrenal cortical carcinoma: aggressive in appearance yet more indolent in behavior?","volume":"166","author":"Mills","year":"2019","journal-title":"Surgery"},{"issue":"3","key":"2025100913171490600_luaf227-B4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/106689690401200304","article-title":"Adrenocortical oncocytic tumors: report of 10 cases and review of the literature","volume":"12","author":"Bisceglia","year":"2004","journal-title":"Int J Surg Pathol"},{"issue":"1","key":"2025100913171490600_luaf227-B5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00428-011-1166-y","article-title":"Adrenocortical neoplasia: evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants","volume":"460","author":"de Krijger","year":"2012","journal-title":"Virchows Arch"},{"key":"2025100913171490600_luaf227-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2016.09.035","article-title":"Validation of the prognostic role of the \u201cHelsinki Score\u201d in 225 cases of adrenocortical carcinoma","volume":"62","author":"Duregon","year":"2017","journal-title":"Hum Pathol"},{"issue":"4","key":"2025100913171490600_luaf227-B7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/PAS.0000000000000574","article-title":"An international Ki67 reproducibility study in adrenal cortical carcinoma","volume":"40","author":"Papathomas","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"2025100913171490600_luaf227-B8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/EO-21-0011","article-title":"Investigating the clinical, pathological and molecular profile of oncocytic adrenocortical neoplasms: a case series and literature review","volume":"1","author":"Fewings","year":"2021","journal-title":"Endocr Oncol"},{"issue":"Suppl 1","key":"2025100913171490600_luaf227-B9","first-page":"1","article-title":"Cabozantinib plus atezolizumab in locally advanced\/metastatic adrenocortical carcinoma: results from a multi-cohort basket phase II trial, CABATEN\/GETNE-T1914 [abstract 1]. 2024 ASCO Genitourinary Cancers Symposium","volume":"42","author":"Enrique","year":"2024","journal-title":"JCO"},{"issue":"3","key":"2025100913171490600_luaf227-B10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.humpath.2014.11.015","article-title":"Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas","volume":"46","author":"Pennanen","year":"2015","journal-title":"Hum Pathol"},{"issue":"1","key":"2025100913171490600_luaf227-B11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ejendo\/lvae077","article-title":"Targeted next generation sequencing molecular profiling and its clinical application in adrenocortical cancer","volume":"191","author":"Cioppi","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2025100913171490600_luaf227-B12","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1210\/jc.2013-2165","article-title":"Molecular screening for a personalized treatment approach in advanced adrenocortical cancer","volume":"98","author":"DeMartino","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025100913171490600_luaf227-B13","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/jclinpath-2014-202514","article-title":"Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies","volume":"67","author":"Ross","year":"2014","journal-title":"J Clin Pathol"},{"issue":"12","key":"2025100913171490600_luaf227-B14","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.18632\/aging.101356","article-title":"A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas","volume":"9","author":"Hadjadj","year":"2017","journal-title":"Aging (Albany NY)"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/11\/luaf227\/64526108\/luaf227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/11\/luaf227\/64526108\/luaf227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:17:21Z","timestamp":1760030241000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf227\/8276500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf227","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,25]]},"article-number":"luaf227"}}